Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR
Hepatitis C virus infection is characterized by chronic liver inflammation and fibrogenesis, leading to end-stage liver failure and hepatocellular carcinoma over the course of 20 to 30 years. It seems not only the chronicity of hepatitis C but also the presence of the virus in non-hepatic tissues cr...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology 2023-04, Vol.58 (4), p.299-310 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 310 |
|---|---|
| container_issue | 4 |
| container_start_page | 299 |
| container_title | Journal of gastroenterology |
| container_volume | 58 |
| creator | Nakagawa, Mina Asahina, Yasuhiro Kakinuma, Sei Okamoto, Ryuichi |
| description | Hepatitis C virus infection is characterized by chronic liver inflammation and fibrogenesis, leading to end-stage liver failure and hepatocellular carcinoma over the course of 20 to 30 years. It seems not only the chronicity of hepatitis C but also the presence of the virus in non-hepatic tissues creates a favorable environment for the potential development of pathogenic impacts on extrahepatic systems and organs. Numerous extra-hepatic manifestations have been reported in association with HCV infection, all of which can substantially affect morbidity, mortality, and quality of life. With the recent development of DAAs, antiviral treatment can cure almost all patients with HCV infection, even those intolerant of or unresponsive to IFN treatment, and several large multicenter studies have confirmed the association of DAA-induced SVR with reductions in liver-related and liver-unrelated complications, such as cardiovascular events, end stage renal disease, and so on. Because, in addition to liver-related diseases, extrahepatic lesions are threatening for patients, it is important to eradicate the virus before these progress and affect life prognosis; in other words, patients should be treated before reaching the point of no return. Tailored surveillance with biomarkers such as M2BPGi and Ang-2, which can be used to identify patients with an elevated risk of EHM, and early prevention or treatment for these patients could improve the morbidity, mortality and QOL. Advancement of both basic and clinical research in this field including the development of more precise biomarkers is highly anticipated. |
| doi_str_mv | 10.1007/s00535-022-01940-1 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2759962428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743457667</galeid><sourcerecordid>A743457667</sourcerecordid><originalsourceid>FETCH-LOGICAL-c532t-f401daef3bf81eb22a59a1342b938c2f3668a448e70dd3602733310937a298913</originalsourceid><addsrcrecordid>eNp9kstu1TAQhi0EoofCC7BAkdiwSRnfkphddURLpUpI3LaWE49bV0l8sJ1KfQjeGaenpSpCyAv7H3_ze0YeQl5TOKIA7fsEILmsgbEaqBJQ0ydkQ0UJScXYU7IBJURNaSsOyIuUrgAoB9k9Jwe8kZ2UQDfk19m0M0OugqswGusHk32YV3mJu3LOPlXb6trHJVUlPvprjHXE0WS0lZltVS_zvbQ-oUmYPlRTiL23Pt_cIkVlM66q2A6XMcx-eGRvXMZYff3x5SV55syY8NXdfki-n3z8tv1Un38-Pdsen9eD5CzXTgC1Bh3vXUexZ8xIZSgXrFe8G5jjTdMZITpswVreAGs55xQUbw1TnaL8kLzb--5i-LlgynryacBxNDOGJWnWSqUaJlhX0Ld_oVdhiXOpTrNOQXlKQftAXZgRtZ9dyNEMq6k-bgUXsm2alTr6B1WWxckPYUbnS_xRAtsnDDGkFNHpXfSTiTeagl5nQO9nQJcZ0LczoNfm3txVvPQT2j8p959eAL4HUrmaLzA-tPQf29_peLp3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890366907</pqid></control><display><type>article</type><title>Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Nakagawa, Mina ; Asahina, Yasuhiro ; Kakinuma, Sei ; Okamoto, Ryuichi</creator><creatorcontrib>Nakagawa, Mina ; Asahina, Yasuhiro ; Kakinuma, Sei ; Okamoto, Ryuichi</creatorcontrib><description>Hepatitis C virus infection is characterized by chronic liver inflammation and fibrogenesis, leading to end-stage liver failure and hepatocellular carcinoma over the course of 20 to 30 years. It seems not only the chronicity of hepatitis C but also the presence of the virus in non-hepatic tissues creates a favorable environment for the potential development of pathogenic impacts on extrahepatic systems and organs. Numerous extra-hepatic manifestations have been reported in association with HCV infection, all of which can substantially affect morbidity, mortality, and quality of life. With the recent development of DAAs, antiviral treatment can cure almost all patients with HCV infection, even those intolerant of or unresponsive to IFN treatment, and several large multicenter studies have confirmed the association of DAA-induced SVR with reductions in liver-related and liver-unrelated complications, such as cardiovascular events, end stage renal disease, and so on. Because, in addition to liver-related diseases, extrahepatic lesions are threatening for patients, it is important to eradicate the virus before these progress and affect life prognosis; in other words, patients should be treated before reaching the point of no return. Tailored surveillance with biomarkers such as M2BPGi and Ang-2, which can be used to identify patients with an elevated risk of EHM, and early prevention or treatment for these patients could improve the morbidity, mortality and QOL. Advancement of both basic and clinical research in this field including the development of more precise biomarkers is highly anticipated.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-022-01940-1</identifier><identifier>PMID: 36585501</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Abdominal Surgery ; Antiviral Agents - therapeutic use ; Biomarkers ; Carcinoma, Hepatocellular - epidemiology ; Carcinoma, Hepatocellular - etiology ; Carcinoma, Hepatocellular - prevention & control ; Chronic infection ; Chronic kidney failure ; Colorectal Surgery ; Control ; Gastroenterology ; Hepacivirus ; Hepatitis C ; Hepatitis C - complications ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - pathology ; Hepatocellular carcinoma ; Hepatology ; Humans ; Infection ; Infections ; Inflammation ; Liver ; Liver diseases ; Liver Neoplasms - epidemiology ; Liver Neoplasms - etiology ; Liver Neoplasms - prevention & control ; Medical research ; Medicine ; Medicine & Public Health ; Medicine, Experimental ; Morbidity ; Mortality ; Patient outcomes ; Patients ; Quality of Life ; Review ; Surgical Oncology ; Sustained Virologic Response ; Type 2 diabetes ; Virus diseases ; Viruses</subject><ispartof>Journal of gastroenterology, 2023-04, Vol.58 (4), p.299-310</ispartof><rights>Japanese Society of Gastroenterology 2022. corrected publication 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. Japanese Society of Gastroenterology.</rights><rights>COPYRIGHT 2023 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c532t-f401daef3bf81eb22a59a1342b938c2f3668a448e70dd3602733310937a298913</citedby><cites>FETCH-LOGICAL-c532t-f401daef3bf81eb22a59a1342b938c2f3668a448e70dd3602733310937a298913</cites><orcidid>0000-0003-1608-7676</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00535-022-01940-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00535-022-01940-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36585501$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakagawa, Mina</creatorcontrib><creatorcontrib>Asahina, Yasuhiro</creatorcontrib><creatorcontrib>Kakinuma, Sei</creatorcontrib><creatorcontrib>Okamoto, Ryuichi</creatorcontrib><title>Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Hepatitis C virus infection is characterized by chronic liver inflammation and fibrogenesis, leading to end-stage liver failure and hepatocellular carcinoma over the course of 20 to 30 years. It seems not only the chronicity of hepatitis C but also the presence of the virus in non-hepatic tissues creates a favorable environment for the potential development of pathogenic impacts on extrahepatic systems and organs. Numerous extra-hepatic manifestations have been reported in association with HCV infection, all of which can substantially affect morbidity, mortality, and quality of life. With the recent development of DAAs, antiviral treatment can cure almost all patients with HCV infection, even those intolerant of or unresponsive to IFN treatment, and several large multicenter studies have confirmed the association of DAA-induced SVR with reductions in liver-related and liver-unrelated complications, such as cardiovascular events, end stage renal disease, and so on. Because, in addition to liver-related diseases, extrahepatic lesions are threatening for patients, it is important to eradicate the virus before these progress and affect life prognosis; in other words, patients should be treated before reaching the point of no return. Tailored surveillance with biomarkers such as M2BPGi and Ang-2, which can be used to identify patients with an elevated risk of EHM, and early prevention or treatment for these patients could improve the morbidity, mortality and QOL. Advancement of both basic and clinical research in this field including the development of more precise biomarkers is highly anticipated.</description><subject>Abdominal Surgery</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biomarkers</subject><subject>Carcinoma, Hepatocellular - epidemiology</subject><subject>Carcinoma, Hepatocellular - etiology</subject><subject>Carcinoma, Hepatocellular - prevention & control</subject><subject>Chronic infection</subject><subject>Chronic kidney failure</subject><subject>Colorectal Surgery</subject><subject>Control</subject><subject>Gastroenterology</subject><subject>Hepacivirus</subject><subject>Hepatitis C</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - pathology</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Infection</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Liver Neoplasms - epidemiology</subject><subject>Liver Neoplasms - etiology</subject><subject>Liver Neoplasms - prevention & control</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Medicine, Experimental</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Quality of Life</subject><subject>Review</subject><subject>Surgical Oncology</subject><subject>Sustained Virologic Response</subject><subject>Type 2 diabetes</subject><subject>Virus diseases</subject><subject>Viruses</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kstu1TAQhi0EoofCC7BAkdiwSRnfkphddURLpUpI3LaWE49bV0l8sJ1KfQjeGaenpSpCyAv7H3_ze0YeQl5TOKIA7fsEILmsgbEaqBJQ0ydkQ0UJScXYU7IBJURNaSsOyIuUrgAoB9k9Jwe8kZ2UQDfk19m0M0OugqswGusHk32YV3mJu3LOPlXb6trHJVUlPvprjHXE0WS0lZltVS_zvbQ-oUmYPlRTiL23Pt_cIkVlM66q2A6XMcx-eGRvXMZYff3x5SV55syY8NXdfki-n3z8tv1Un38-Pdsen9eD5CzXTgC1Bh3vXUexZ8xIZSgXrFe8G5jjTdMZITpswVreAGs55xQUbw1TnaL8kLzb--5i-LlgynryacBxNDOGJWnWSqUaJlhX0Ld_oVdhiXOpTrNOQXlKQftAXZgRtZ9dyNEMq6k-bgUXsm2alTr6B1WWxckPYUbnS_xRAtsnDDGkFNHpXfSTiTeagl5nQO9nQJcZ0LczoNfm3txVvPQT2j8p959eAL4HUrmaLzA-tPQf29_peLp3</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Nakagawa, Mina</creator><creator>Asahina, Yasuhiro</creator><creator>Kakinuma, Sei</creator><creator>Okamoto, Ryuichi</creator><general>Springer Nature Singapore</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1608-7676</orcidid></search><sort><creationdate>20230401</creationdate><title>Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR</title><author>Nakagawa, Mina ; Asahina, Yasuhiro ; Kakinuma, Sei ; Okamoto, Ryuichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c532t-f401daef3bf81eb22a59a1342b938c2f3668a448e70dd3602733310937a298913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Abdominal Surgery</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biomarkers</topic><topic>Carcinoma, Hepatocellular - epidemiology</topic><topic>Carcinoma, Hepatocellular - etiology</topic><topic>Carcinoma, Hepatocellular - prevention & control</topic><topic>Chronic infection</topic><topic>Chronic kidney failure</topic><topic>Colorectal Surgery</topic><topic>Control</topic><topic>Gastroenterology</topic><topic>Hepacivirus</topic><topic>Hepatitis C</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - pathology</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Infection</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Liver Neoplasms - epidemiology</topic><topic>Liver Neoplasms - etiology</topic><topic>Liver Neoplasms - prevention & control</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Medicine, Experimental</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Quality of Life</topic><topic>Review</topic><topic>Surgical Oncology</topic><topic>Sustained Virologic Response</topic><topic>Type 2 diabetes</topic><topic>Virus diseases</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakagawa, Mina</creatorcontrib><creatorcontrib>Asahina, Yasuhiro</creatorcontrib><creatorcontrib>Kakinuma, Sei</creatorcontrib><creatorcontrib>Okamoto, Ryuichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakagawa, Mina</au><au>Asahina, Yasuhiro</au><au>Kakinuma, Sei</au><au>Okamoto, Ryuichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>58</volume><issue>4</issue><spage>299</spage><epage>310</epage><pages>299-310</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Hepatitis C virus infection is characterized by chronic liver inflammation and fibrogenesis, leading to end-stage liver failure and hepatocellular carcinoma over the course of 20 to 30 years. It seems not only the chronicity of hepatitis C but also the presence of the virus in non-hepatic tissues creates a favorable environment for the potential development of pathogenic impacts on extrahepatic systems and organs. Numerous extra-hepatic manifestations have been reported in association with HCV infection, all of which can substantially affect morbidity, mortality, and quality of life. With the recent development of DAAs, antiviral treatment can cure almost all patients with HCV infection, even those intolerant of or unresponsive to IFN treatment, and several large multicenter studies have confirmed the association of DAA-induced SVR with reductions in liver-related and liver-unrelated complications, such as cardiovascular events, end stage renal disease, and so on. Because, in addition to liver-related diseases, extrahepatic lesions are threatening for patients, it is important to eradicate the virus before these progress and affect life prognosis; in other words, patients should be treated before reaching the point of no return. Tailored surveillance with biomarkers such as M2BPGi and Ang-2, which can be used to identify patients with an elevated risk of EHM, and early prevention or treatment for these patients could improve the morbidity, mortality and QOL. Advancement of both basic and clinical research in this field including the development of more precise biomarkers is highly anticipated.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>36585501</pmid><doi>10.1007/s00535-022-01940-1</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-1608-7676</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0944-1174 |
| ispartof | Journal of gastroenterology, 2023-04, Vol.58 (4), p.299-310 |
| issn | 0944-1174 1435-5922 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2759962428 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Abdominal Surgery Antiviral Agents - therapeutic use Biomarkers Carcinoma, Hepatocellular - epidemiology Carcinoma, Hepatocellular - etiology Carcinoma, Hepatocellular - prevention & control Chronic infection Chronic kidney failure Colorectal Surgery Control Gastroenterology Hepacivirus Hepatitis C Hepatitis C - complications Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - pathology Hepatocellular carcinoma Hepatology Humans Infection Infections Inflammation Liver Liver diseases Liver Neoplasms - epidemiology Liver Neoplasms - etiology Liver Neoplasms - prevention & control Medical research Medicine Medicine & Public Health Medicine, Experimental Morbidity Mortality Patient outcomes Patients Quality of Life Review Surgical Oncology Sustained Virologic Response Type 2 diabetes Virus diseases Viruses |
| title | Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T00%3A51%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20eradication%20of%20hepatitis%20C%20virus%20on%20liver-related%20and%20-unrelated%20diseases:%20morbidity%20and%20mortality%20of%20chronic%20hepatitis%20C%20after%20SVR&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Nakagawa,%20Mina&rft.date=2023-04-01&rft.volume=58&rft.issue=4&rft.spage=299&rft.epage=310&rft.pages=299-310&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-022-01940-1&rft_dat=%3Cgale_proqu%3EA743457667%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890366907&rft_id=info:pmid/36585501&rft_galeid=A743457667&rfr_iscdi=true |